Outcomes of intravitreal aflibercept (Eylea®) treatment for treatment-naïve contralateral eyes with neovascular age-related macular degeneration in patients whose treatment failed with intravitreal ranibizumab in the first eye

Trial Profile

Outcomes of intravitreal aflibercept (Eylea®) treatment for treatment-naïve contralateral eyes with neovascular age-related macular degeneration in patients whose treatment failed with intravitreal ranibizumab in the first eye

Completed
Phase of Trial: Phase IV

Latest Information Update: 15 Dec 2017

At a glance

  • Drugs Aflibercept (Primary)
  • Indications Age-related macular degeneration
  • Focus Therapeutic Use
  • Acronyms Eylea IIT
  • Most Recent Events

    • 15 Dec 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top